Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BeneI-G
- Development stage
- Unknown
- Lead developer
- Chinoin
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
BeneI-G is a probiotic dietary supplement developed by Chinoin in partnership with AB-Biotics and Kaneka Probiotics. It is formulated with a patented blend of four probiotic strains—Lactiplantibacillus plantarum KABP-033 (CECT 30292), Lactiplantibacillus plantarum KABP-022 (CECT 7484), Lactiplantibacillus plantarum KABP-023 (CECT 7485), and Pediococcus acidilactici KABP-021 (CECT 7483)—along with Vitamin D3 (cholecalciferol). The supplement is designed to support and maintain intestinal health, balance the gut microbiota, and strengthen the immune system, particularly in reducing the duration and severity of viral upper respiratory tract infections (URIs) and supporting recovery from respiratory illnesses.
- Brand names
- AB-ImmuneBeneI-GKovirvinPANABIOTICS IMMUN aB21Probio7 Professionals AB21Probio-7 Professionals AB21Probio 7 Professionals AB21Xebevir
- Other names
- AB21 probiotic blendAB-21 probiotic blendAB 21 probiotic blendLactiplantibacillus plantarum KABP-022 + Lactiplantibacillus plantarum KABP-023 + Lactiplantibacillus plantarum KABP-033 + Pediococcus acidilactici KABP-021 + cholecalciferolLactobacillus plantarum CECT 7484 + Lactobacillus plantarum CECT 7485 + Lactobacillus plantarum CECT 30292 + Pediococcus acidilactici CECT 7483 + vitamin D3
02
Targets
VDR (Vitamin D receptor)
Beyond the preview
Go deeper on BeneI-G.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BeneI-G.